Furthermore, our study reveals that ER + /PR- breast tumors exhibit a higher incidence of variants in TP53, ERBB2, CDK12, SPEN, and NEB, with variant rates of 65%, 42%, 27%, 13%, and 10%, respectively. This evidence concerns the gene TP53 and breast neoplasm.